The World Health Organization has issued formal guidance on GLP-1 drugs for treating obesity, laying out conditional recommendations, equity concerns and steps for wider access. The guidance frames obesity as a chronic, complex disease and positions GLP-1 therapies as a new tool alongside behavioral care. It stresses that benefits are clear but long-term safety, cost and system readiness remain open questions.
GLP-1 medications mimic the hormone glucagon-like peptide-1 and are already in use for people with type 2 diabetes and for medical weight management. They work by affecting appetite and glucose regulation, which explains both their diabetes and weight-loss effects. Clinicians and health systems are watching closely as clinical use expands beyond diabetes care.
WHO released the guideline to confront what it calls the growing global health challenge of obesity and to offer a framework for safe, equitable use of these medicines. Obesity affects more than one billion people worldwide and has been tied to millions of deaths annually. Projections show the number of people with obesity rising substantially in the coming years.
Earlier, GLP-1 drugs were added to WHO’s Essential Medicines List for managing type 2 diabetes in high-risk groups, and the new guidance extends recommendations into obesity treatment. The agency introduced two conditional recommendations that aim to balance clinical potential with public health realities. Those conditions are meant to guide policymakers and clinicians while more evidence accumulates.
“GLP-1 therapies may be used by adults, but excluding pregnant women, for the long-term treatment of obesity,” the guidance states verbatim. “While the efficacy of these therapies in treating obesity and improving metabolic and other outcomes was evident, the recommendation is conditional due to limited data on their long-term efficacy and safety, maintenance and discontinuation, their current costs, inadequate health-system preparedness and potential equity implications.”
The second conditional recommendation emphasizes combining medication with intensive behavioral support, not using drugs in isolation. That includes healthy diets, regular physical activity and professional support as part of a comprehensive approach. WHO is clear that effective obesity care requires coordinated behavioral and clinical strategies.
The economic stakes are large: the global economic burden of obesity is projected to soar, potentially reaching trillions annually in the near future. WHO frames the guidance as a tool to curb rising costs linked to obesity and its complications. Even with ramped-up production, the agency estimates that by 2030 fewer than 10% of people who might benefit will actually receive these therapies.
“Without deliberate policies, access to these therapies could exacerbate existing health disparities,” WHO warned, calling for proactive measures. “The guideline calls on the global community to consider strategies to expand access, such as pooled procurement, tiered pricing and voluntary licensing among others,” the document urges. Those measures are aimed at preventing wealthy markets from monopolizing supply while poorer regions remain underserved.
WHO Director-General Dr. Tedros Adhanom Ghebreyesus framed obesity as a global priority in his statement, noting it is a “major global health challenge that WHO is committed to addressing by supporting countries and people worldwide to control it, effectively and equitably.” He added, “Our new guidance recognizes that obesity is a chronic disease that can be treated with comprehensive and lifelong care.” Those lines underline WHO’s push for sustained, system-level responses.
The agency also reminds readers that obesity contributes to cardiovascular disease, type 2 diabetes and some cancers, reinforcing the case for early screening and intervention. While GLP-1 therapies are described as the first clearly efficacious pharmacologic option for adults with obesity, WHO insists broader public-health actions are essential. Creating healthier environments, protecting high-risk individuals through screening, and assuring ongoing access to care are all parts of the recommended strategy.
